SE504922C2 - Terapeutisk komposition för behandling av chocktillstånd, där sagda komposition innehåller derivat av L-arginin tillsammans med en cyklooxygenasblockerare - Google Patents
Terapeutisk komposition för behandling av chocktillstånd, där sagda komposition innehåller derivat av L-arginin tillsammans med en cyklooxygenasblockerareInfo
- Publication number
- SE504922C2 SE504922C2 SE9003974A SE9003974A SE504922C2 SE 504922 C2 SE504922 C2 SE 504922C2 SE 9003974 A SE9003974 A SE 9003974A SE 9003974 A SE9003974 A SE 9003974A SE 504922 C2 SE504922 C2 SE 504922C2
- Authority
- SE
- Sweden
- Prior art keywords
- therapeutic composition
- treatment
- cyclooxygenase
- perfusion
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 title claims abstract description 9
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 title claims abstract description 9
- 230000035939 shock Effects 0.000 title claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 8
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 230000010412 perfusion Effects 0.000 claims abstract description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- -1 amino, methylamino, ethylamino Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 7
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 7
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000002981 blocking agent Substances 0.000 description 5
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 4
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229960005192 methoxamine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polyurethanes Or Polyureas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898929076A GB8929076D0 (en) | 1989-12-22 | 1989-12-22 | Treatment of shock by blocking agents of edrf effect or formation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9003974D0 SE9003974D0 (sv) | 1990-12-12 |
| SE9003974L SE9003974L (sv) | 1991-06-23 |
| SE504922C2 true SE504922C2 (sv) | 1997-05-26 |
Family
ID=10668428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9003974A SE504922C2 (sv) | 1989-12-22 | 1990-12-12 | Terapeutisk komposition för behandling av chocktillstånd, där sagda komposition innehåller derivat av L-arginin tillsammans med en cyklooxygenasblockerare |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5081148A (OSRAM) |
| JP (1) | JP2706578B2 (OSRAM) |
| KR (1) | KR950005866B1 (OSRAM) |
| AT (1) | AT403122B (OSRAM) |
| AU (1) | AU629777B2 (OSRAM) |
| BE (1) | BE1005531A5 (OSRAM) |
| CA (1) | CA2032904C (OSRAM) |
| CH (1) | CH681692A5 (OSRAM) |
| DE (1) | DE4041283C2 (OSRAM) |
| DK (1) | DK176168B1 (OSRAM) |
| FR (1) | FR2656220B1 (OSRAM) |
| GB (2) | GB8929076D0 (OSRAM) |
| HK (1) | HK134693A (OSRAM) |
| IE (1) | IE64403B1 (OSRAM) |
| IT (1) | IT1246511B (OSRAM) |
| LU (1) | LU87867A1 (OSRAM) |
| MY (1) | MY105328A (OSRAM) |
| NL (1) | NL194717C (OSRAM) |
| OA (1) | OA09337A (OSRAM) |
| SE (1) | SE504922C2 (OSRAM) |
| ZA (1) | ZA9010004B (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE468881B (sv) * | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar |
| GB9127376D0 (en) * | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| GB9200114D0 (en) * | 1992-01-04 | 1992-02-26 | Scras | Dual inhibitors of no synthase and cyclooxygenase |
| US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| US5585402A (en) * | 1992-12-23 | 1996-12-17 | Glaxo Wellcome Inc. | Nitric oxide synthase inhibitors |
| US5436270A (en) * | 1993-04-07 | 1995-07-25 | National Science Council | Method for protecting against endotoxin-induced shock |
| GB9312204D0 (en) * | 1993-06-14 | 1993-07-28 | Zeneca Ltd | Therapeutic composition |
| GB9312761D0 (en) * | 1993-06-21 | 1993-08-04 | Wellcome Found | Amino acid derivatives |
| US6225305B1 (en) | 1993-10-04 | 2001-05-01 | Glaxo Wellcome Inc. | Substituted urea and isothiorea derivatives as no synthase inhibitors |
| US6090846A (en) * | 1994-06-01 | 2000-07-18 | Glaxo Wellcome Inc. | Substituted urea and isothiourea derivatives as no synthase inhibitors |
| US6297276B1 (en) | 1993-10-04 | 2001-10-02 | Glaxosmithkline | Substituted urea and isothiourea derivatives as no synthase inhibitors |
| EP0724570B1 (en) | 1993-10-21 | 1999-03-03 | G.D. Searle & Co. | Amidino derivatives useful as nitric oxide synthase inhibitors |
| JPH09504524A (ja) * | 1993-10-21 | 1997-05-06 | ジー．ディー．サール アンド カンパニー | 酸化窒素シンターゼ阻害剤として有用なアミジノ誘導体 |
| GB9404400D0 (en) * | 1994-03-07 | 1994-04-20 | Wood Pauline J | Potentiation of bioreductive agents |
| WO1995024382A1 (en) * | 1994-03-10 | 1995-09-14 | G.D. Searle & Co. | L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors |
| US5684008A (en) * | 1994-11-09 | 1997-11-04 | G. D. Searle & Co. | Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
| FR2727111B1 (fr) * | 1994-11-21 | 1997-01-17 | Hoechst Lab | Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments |
| KR100517210B1 (ko) * | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | 통증,염증및경련억제용관주용액 |
| AU4467396A (en) * | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| ATE532530T1 (de) * | 1994-12-12 | 2011-11-15 | Omeros Corp | Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und/oder spasmen an einer gefässstruktur |
| FR2730930B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique |
| GB9504350D0 (en) * | 1995-03-04 | 1995-04-26 | Sod Conseils Rech Applic | Arginine derivatives |
| CA2216882A1 (en) * | 1995-04-20 | 1996-10-24 | G.D. Searle & Co. | Cyclic amidino agents useful as nitric oxide synthase inhibitors |
| US5830917A (en) * | 1995-09-11 | 1998-11-03 | G. D. Searle & Co. | L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors |
| US5945408A (en) * | 1996-03-06 | 1999-08-31 | G.D. Searle & Co. | Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors |
| US5981511A (en) * | 1996-03-06 | 1999-11-09 | G.D. Searle & Co. | Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors |
| US6369272B1 (en) | 1997-01-13 | 2002-04-09 | Glaxosmithkline | Nitric oxide synthase inhibitors |
| US6620848B2 (en) | 1997-01-13 | 2003-09-16 | Smithkline Beecham Corporation | Nitric oxide synthase inhibitors |
| US5981556A (en) * | 1997-07-22 | 1999-11-09 | G.D. Searle & Co. | 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| JP2002517502A (ja) | 1998-06-10 | 2002-06-18 | ジー・ディー・サール・アンド・カンパニー | 複素二環状及び三環状一酸化窒素シンターゼ阻害剤 |
| US6344473B1 (en) | 2000-08-07 | 2002-02-05 | G.D. Searle & Co. | Imidazoles useful as nitric oxide synthase inhibitors |
| KR101123429B1 (ko) | 2003-12-30 | 2012-06-29 | 바조팜 게엠베하 | 4-아미노-7,8-다이하이드로프테리다인, 이를 함유한 약학조성물 및 산화 질소 수준의 증가에 의해 야기되는 질병의치료를 위한 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB931921A (en) * | 1960-12-22 | 1963-07-24 | Lab Roques | Therapeutic compositions intended for the treatment of any hepatic malfunctionings |
| DE1767212B1 (de) * | 1967-04-13 | 1971-05-06 | Sumitomo Chemical Co | Verfahren zur Herstellung injizierbarer Arzneimittel |
| FR2115060A1 (en) * | 1970-11-26 | 1972-07-07 | Metabio | Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin |
| CA1029660A (en) * | 1973-06-01 | 1978-04-18 | Kyowa Hakko Kogyo Co. | Prevention of gastric lesions |
| FR2320759A1 (fr) * | 1975-08-11 | 1977-03-11 | Union Pharma Scient Appl | Solution d'acide acetylsalicylique extemporanee injectable |
| IT1127321B (it) * | 1979-12-28 | 1986-05-21 | Italfarmaco Spa | Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi |
| IT1127322B (it) * | 1979-12-28 | 1986-05-21 | Italfarmaco Spa | Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici |
| JPS5781409A (en) * | 1980-11-10 | 1982-05-21 | Toko Yakuhin Kogyo Kk | External plaster |
| JPS57197211A (en) * | 1981-05-28 | 1982-12-03 | Sumitomo Chem Co Ltd | Useful eye drop composition |
| JPS57200361A (en) * | 1981-06-03 | 1982-12-08 | Sumitomo Chem Co Ltd | "indomethacin(r)" pharmaceutical with low irritant action |
| JPH0236570B2 (ja) * | 1985-05-30 | 1990-08-17 | Toko Yakuhin Kogyo Kk | Shoenchintsunankozai |
| JPS6239524A (ja) * | 1985-08-13 | 1987-02-20 | Toko Yakuhin Kogyo Kk | 消炎鎮痛軟膏剤 |
| IT1201511B (it) * | 1985-12-23 | 1989-02-02 | Italfarmaco Spa | Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono |
| AU1489688A (en) * | 1987-02-20 | 1988-09-14 | Shriners Hospitals For Crippled Children | Omega-3 fatty acids in traumatic injury treatment |
-
1989
- 1989-12-22 GB GB898929076A patent/GB8929076D0/en active Pending
-
1990
- 1990-12-11 NL NL9002720A patent/NL194717C/nl not_active IP Right Cessation
- 1990-12-12 SE SE9003974A patent/SE504922C2/sv not_active IP Right Cessation
- 1990-12-12 ZA ZA9010004A patent/ZA9010004B/xx unknown
- 1990-12-14 BE BE9001200A patent/BE1005531A5/fr not_active IP Right Cessation
- 1990-12-18 IT IT02241390A patent/IT1246511B/it active IP Right Grant
- 1990-12-19 US US07/630,273 patent/US5081148A/en not_active Expired - Lifetime
- 1990-12-19 IE IE459290A patent/IE64403B1/en not_active IP Right Cessation
- 1990-12-19 CH CH4034/90A patent/CH681692A5/fr not_active IP Right Cessation
- 1990-12-19 FR FR9015904A patent/FR2656220B1/fr not_active Expired - Fee Related
- 1990-12-20 MY MYPI90002223A patent/MY105328A/en unknown
- 1990-12-20 AT AT0260690A patent/AT403122B/de not_active IP Right Cessation
- 1990-12-21 DE DE4041283A patent/DE4041283C2/de not_active Expired - Fee Related
- 1990-12-21 DK DK199003041A patent/DK176168B1/da not_active IP Right Cessation
- 1990-12-21 OA OA59932A patent/OA09337A/xx unknown
- 1990-12-21 KR KR1019900021355A patent/KR950005866B1/ko not_active Expired - Fee Related
- 1990-12-21 LU LU87867A patent/LU87867A1/fr unknown
- 1990-12-21 CA CA002032904A patent/CA2032904C/en not_active Expired - Lifetime
- 1990-12-21 AU AU68376/90A patent/AU629777B2/en not_active Ceased
- 1990-12-24 GB GB9028013A patent/GB2240041B/en not_active Expired - Lifetime
- 1990-12-25 JP JP2419113A patent/JP2706578B2/ja not_active Expired - Lifetime
-
1993
- 1993-12-09 HK HK1346/93A patent/HK134693A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE504922C2 (sv) | Terapeutisk komposition för behandling av chocktillstånd, där sagda komposition innehåller derivat av L-arginin tillsammans med en cyklooxygenasblockerare | |
| EP1094803A2 (en) | Use of gaba-analogues for treating insomia | |
| RU2003109440A (ru) | Производные 5-амидино-2-гидроксибензолсульфонамида, содержащие их фармацевтические композиции и промежуточные продукты для их получения | |
| US4540582A (en) | Treatment of seizure disorders and pharmaceutical compositions useful therein | |
| BR112020003735A2 (pt) | método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais | |
| Esplugues et al. | Nitric oxide mediates the inhibition by interleukin‐1β of pentagastrin‐stimulated rat gastric acid secretion | |
| US4595697A (en) | Treatment of seizure disorders and pharmaceutical compositions useful therein | |
| CA2332929C (en) | Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles | |
| EP0715850B1 (en) | Use of proline and/or derivatives as an antihepatitis agent | |
| US5714516A (en) | Anti-viral agents | |
| WO2003075905A1 (es) | Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la expresion de l-selectinas y de la isoforma inductible de la sintasa del oxido nitrico | |
| RU2270672C1 (ru) | Способ профилактики и лечения системного амилоидоза и его нефропатической формы у экспериментальных животных | |
| RU2684783C1 (ru) | Композиция антиоксидантов, пригодная для перорального применения в терапии воспалительного процесса в легких | |
| US5478815A (en) | Liver protectant tocophery-ascorbyl-phosphate | |
| US20030045500A1 (en) | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles | |
| RU2228741C2 (ru) | Способ лечения рецидивирующего иридоциклохориоидита лошадей | |
| RU2223756C1 (ru) | Способ лечения рецидивирующего иридоциклохориоидита лошадей | |
| Linée et al. | Bml 40696: a novel potent inhibitor of the cardiac sarcoplasmic reticulum-bound phosphodiesterase, with positive inotropic and lusitropic properties | |
| JPH02131421A (ja) | 肝障害抑制剤 | |
| JPH08208472A (ja) | 抗肝炎剤 | |
| JPS5935365B2 (ja) | 肝疾患治療薬 | |
| MXPA00011510A (en) | Pharmaceutical composition containinig gaba analogs and an antiviral agent to treat shingles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |